Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach

Tommaso Clemente(Vita-Salute San Raffaele University), Vincenzo Spagnuolo(Vita-Salute San Raffaele University), Diana Canetti(Vita-Salute San Raffaele University), Emanuela Messina(Vita-Salute San Raffaele University), Antonella Castagna(Vita-Salute San Raffaele University), Elisabetta Carini, Rebecka Papaioannu Borjesson(Vita-Salute San Raffaele University), Liviana Della Torre(Vita-Salute San Raffaele University)
JAC-Antimicrobial Resistance
May 6, 2024
10.1093/jacamr/dlae074
Cited by 1

Related Papers

Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency
|Critical Care and Resuscitation|2020|229
Mpox in people with past infection or a complete vaccination course: a global case series
|The Lancet Infectious Diseases|2023|141
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
|BMJ Open|2024|21
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study
|Open Forum Infectious Diseases|2024|20
Persistent ocular mpox infection in an immunocompetent individual
|The Lancet Infectious Diseases|2023|18